Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

mon adverse events among patients receiving Viread with other antiretroviral agents in a pivotal clinical study (Study 903) were mild to moderate gastrointestinal events and dizziness. Moderate to severe adverse events occurring in more than 5 percent of patients receiving Viread included rash (rash, pruritis, maculopapular rash, urticaria, vesiculobullous rash and pustular rash), headache, pain, diarrhea, depression, back pain, fever, nausea, abdominal pain, asthenia (weakness) and anxiety. In another pivotal study (Study 907), less than 1 percent of patients discontinued participation because of gastrointestinal events.

It is important for patients to be aware that anti-HIV medicines including Viread do not cure HIV infection or AIDS and do not reduce the risk of transmitting HIV to others. Full prescribing information is available at www.GileadHIV.com.

The parent compound of Viread was discovered through a collaborative research effort between Dr. Antonin Holy, Institute for Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in Prague and Dr. Erik DeClercq, Rega Institute for Medical Research, Katholic University in Leuven, Belgium.

About Hepsera

Hepsera, a nucleotide analogue for the treatment of chronic hepatitis B, works by inhibiting HBV DNA polymerase, an enzyme involved in the replication of the virus in the body.

In the United States, Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

The adverse reactions considered at least possibly related to treatment reported in 3 percent or greater of patients in the first 48 weeks in Hepsera pivotal clinical studies were asthenia, headache, abdominal pain, nausea, flatulence, diarrhea and dyspepsia. With extended treatment, mild to moderate increases in serum cre
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/11/2014)... Virginia (PRWEB) July 11, 2014 ASHBURN PSYCHOLOGICAL ... took effect, which allows individuals with an intellectual disability or ... of their licenses and ID cards to alert law enforcement ... a condition. The idea was inspired by a central ... in protecting her 9 year old autistic son, JP. ...
(Date:7/10/2014)... More than 200 experts on aggression, who research ... will attend the 21st World Meeting of the ... the Loews Atlanta Hotel, July 15-19. , Georgia ... which is held every other year on alternating continents. ... scholars from more than 20 different countries, which will ...
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... 10, 2014 A Forever Recovery ... gets clients off to a great start and gives ... in, has launched a new Eating Disorders section of ... section highlights:, , Different types of ... of Mental Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Nature, not nurture, may play ... chimpanzees, a new study finds. "As is the ... cognitive [thinking] abilities in chimpanzees," William Hopkins of the ... a news release from the journal Current Biology ... the evolution of intelligence in humans, Hopkins, team said. ...
Breaking Medicine News(10 mins):Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2
... research reports published in the new issue of Archives ... vascular birthmarks with treatment procedures like laser therapy and ... internal, or form an external birthmark and can be ... ,The researchers had presented the current treatment approaches for ...
... genetic disorder characterized by distorted, sickle shaped red blood cells. ... damage to the kidneys, spleen, and liver. The sickle cell ... is about 1 in 500., ,Despite much clinical work, ... can be relieved, and the frequency and duration of the ...
... Researchers at the University of California in San Francisco ... fruit and vegetables can reduce the risk of pancreatic ... most strongly associated with increased // protection were onions, ... potatoes, corn and yellow squash), dark leafy vegetables and ...
... medical journal The Lancet had published a research ... health workers., ,Poor health-worker performance is a ... In the current issue of The Lancet researchers ... for how high-quality health-worker performance can be achieved., ...
... Molecular Immunologist and his team has found a new virus ... inflammation and autoimmune diseases. The new delivery system acts as ... virus containing the required genes are transferred into the T ... the immune cells they get attracted towards the cancer cell ...
... have been reported to experience 25% less muscle and joint ... active. Furthermore, the study has also revealed that people who ... experience less pain than non-runners even though they are more ... study involved comparison of the level of pain in a ...
Cached Medicine News:Health News:Hydroxyurea Treatment For Children With Sickle Cell Disease 2
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Premilene Mesh LP Self-Forming Plug is combining ... This results in a very soft hernia plug ... to standard Plugs less foreign body material is ... the hernia size and shape allows for a ...
... Celsius Control System provides physicians,with ... safely,and rapidly lower patient body ... temperature and,rewarm patients to normothermic ... consists of an endovascular,catheter, console ...
... Fiberoptics Gemini surgical headlight is perfectly balanced ... durable and ultra-low-profile and illuminates brilliantly while ... annoying "rams effect." The fully adjustable headband, ... to sit low on the brow, directing ...
Medicine Products: